U.S. Markets closed

Second Sight Medical, Investors Open Their Eyes Making These Shares Soar, Recent Developments

NEW YORK, NY / ACCESSWIRE / February 7, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive report with no obligation on Second Sight Medical Products, Inc. (EYES) a company that develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the United States, Italy, Germany, France, and Canada. The company's product is the Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Recently, the company announced they had implanted a record number of its Argus™ II Retinal Prosthesis Systems in 2017. Further, the company announced the first implantation of its Orion™ Cortical Visual Prosthesis System in a human patient.

EYES shares have gained 28% in February and have more than doubled in value since the beginning of November 2017. Trading volumes have been significantly higher in February.

Review recent EYES milestones, analysts opinion, and get a financial report: READ MORE.

Copy and paste to your browser may be required to view the report - http://bit.ly/2C03CJa-EYES-Analyst.

In a healthy eye, the photoreceptors (rods and cones) in the retina convert light into tiny electrochemical impulses that are sent through the optic nerve and into the brain, where they are decoded into images. If the photoreceptors no longer function correctly - due to conditions such as retinitis pigmentosa - the first step in this process is disrupted, and the visual system cannot transform light into images.

The Argus II System implant is an epiretinal prosthesis surgically implanted in and on the eye, that includes an antenna, an electronics case, and an electrode array.

Get info on the EYES prosthesis systems and how they work, along with chart data: READ MORE.

Copy and paste to your browser may be required to view the report - http://bit.ly/2C03CJa-EYES-Analyst.


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE: Traders News Source